Prosecution Insights
Last updated: August 14, 2026

BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready

Portfolio Summary

6
Total Pending OAs
5
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

4
Hard (67%)
1
Medium (17%)
1
Easy (17%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (17%)
§112 only1 (17%)
Multi-statute (no §101)4 (67%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

5
Life Sciences
83% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
1
Business / Other
17% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

60 h
Manual time on pending OAs
12 h
Time saved (low, 20%)
21 h
Time saved (mid, 35%)
0.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
KIM, TAEYOON 1 51.6% +51.8%
PRONZATI, GINA 1 65.7% +45.2%
VIVLEMORE, TRACY ANN 1 73.0% +6.7%
TINSLEY, BRENDAN THOMAS 1 61.9% +70.5%
SINGH, ANOOP KUMAR 1 42.8% +67.4%
ABBOTT, KODYE LEE 1 57.7% +64.7%

Hard Cases (4)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18702039 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENES KIM, TAEYOON
18287574 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC IL1RAP PRONZATI, GINA
17640592 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC TNFR2 SINGH, ANOOP KUMAR
17631048 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC IL33 ABBOTT, KODYE LEE

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
17790059 GENETICALLY MODIFIED IMMUNODEFICIENT NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPa/CD47 TINSLEY, BRENDAN THOMAS 3d overdue
18702039 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENES KIM, TAEYOON
18287574 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC IL1RAP PRONZATI, GINA
17640592 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC TNFR2 SINGH, ANOOP KUMAR
17631048 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC IL33 ABBOTT, KODYE LEE

Top Art Units

Art UnitApps
1634 2
1633 1
1638 1
1632 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18702039 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENES KIM, TAEYOON §102§103 Non-Final OA Pending Apr 17, 2024
18287574 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC IL1RAP PRONZATI, GINA 1633 §102§103 Non-Final OA Pending Oct 19, 2023
18273631 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC FCRN VIVLEMORE, TRACY ANN 1638 §103 Non-Final OA 28d overdue Pending Jul 21, 2023
17790059 GENETICALLY MODIFIED IMMUNODEFICIENT NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPa/CD47 TINSLEY, BRENDAN THOMAS 1634 §112 Final Rejection 3d overdue Pending Jun 29, 2022
17640592 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC TNFR2 SINGH, ANOOP KUMAR 1632 §103§112 Non-Final OA Pending Mar 04, 2022
17631048 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC IL33 ABBOTT, KODYE LEE 1634 §103§112 Non-Final OA Pending Jan 28, 2022

Managing BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month